3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
84
Lung Neoplasms
39
Carcinoma, Hepatocellular
38
Small Cell Lung Carcinoma
26
Breast Neoplasms
19
Neoplasms
18
Cholangiocarcinoma
18
Urinary Bladder Neoplasms
17
Colorectal Neoplasms
15
Triple Negative Breast Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
12
Pancreatic Neoplasms
10
Liver Neoplasms
10
Biliary Tract Neoplasms
10
Recurrence
9
Ovarian Neoplasms
9
Neoplasm Metastasis
9
Esophageal Neoplasms
8
Carcinoma, Renal Cell
8
Stomach Neoplasms
7
Head and Neck Neoplasms
7
Carcinoma, Transitional Cell
7
Prostatic Neoplasms
6
Melanoma
6
Endometrial Neoplasms
6
Bile Duct Neoplasms
6
Uterine Cervical Neoplasms
5
Neoplasms by Site
5
Mesothelioma, Malignant
5
Adenocarcinoma
5
Interventions
anlotinib
2
Sunitinib
2
Ocoxin
2
Carboplatin
2
Bevacizumab
2
sipuleucel-T
1
pembrolizumab
1
palbociclib
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
lenvatinib
1
ixabepilone
1
durvalumab
1
catumaxomab
1
Sorafenib
1
Radiotherapy, Intensity-Modulated
1
Paclitaxel
1
Leuprolide
1
Immunotherapy
1
Filgrastim
1
Cisplatin
1
Chemoradiotherapy
1
CP protocol
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Glandular and Epithelial
×
durvalumab
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled